Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression Sekulic, A., Hainsworth, J. D., Lewis, K. D., Oro, A. E., Gesierich, A., Mortier, L., Dirix, L., Bernard, S., Dreno, B., Murrell, D. F., Williams, S., Hou, J., Fisher, D. MOSBY-ELSEVIER. 2015: AB195

View details for Web of Science ID 000360942901499